Promazine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| ||
| Image:Promazine3d.png | ||
| Promazine
| ||
| Systematic (IUPAC) name | ||
| N,N-dimethyl-3-(10H-phenothiazin-10-yl) propan-1-amine | ||
| Identifiers | ||
| CAS number | ||
| ATC code | N05 | |
| PubChem | ||
| DrugBank | ||
| Chemical data | ||
| Formula | C17H20N2S | |
| Mol. mass | 284.42 g/mol | |
| Pharmacokinetic data | ||
| Bioavailability | ? | |
| Protein binding | 94% | |
| Metabolism | ? | |
| Half life | ? | |
| Excretion | ? | |
| Therapeutic considerations | ||
| Pregnancy cat. |
? | |
| Legal status | ||
| Routes | ? | |
|
WikiDoc Resources for Promazine | |
|
Articles | |
|---|---|
|
Most recent articles on Promazine | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Promazine at Clinical Trials.gov Clinical Trials on Promazine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Promazine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Promazine Discussion groups on Promazine Directions to Hospitals Treating Promazine Risk calculators and risk factors for Promazine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Promazine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch. Promazine (marketed as Sparine) is a medication that belongs to the phenothiazine class of antipsychotics. An older medication used to treat schizophrenia, its use has largely been replaced by newer agents such as olanzapine and quetiapine.
It has predominantly anticholinergic side effects, though extrapyramidal side effects are not uncommon either.
Psycholeptics: antipsychotics (N05A) | |
|---|---|
| Phenothiazine typical antipsychotics | Chlorpromazine • Fluphenazine • Mesoridazine • Perphenazine • Prochlorperazine • Promazine • Thioridazine/Sulforidazine • Trifluoperazine • Triflupromazine |
| Other typical antipsychotics | Indoles (Molindone) • Butyrophenones (Azaperone, Benperidol, Bromperidol, Droperidol, Haloperidol, Trifluperidol) • Thioxanthenes (Flupentixol, Chlorprothixene, Thiothixene, Zuclopenthixol) • diphenylbutylpiperidines (Fluspirilene, Penfluridol, Pimozide) • other (Loxapine) |
| Atypical antipsychotics | Butyrophenones (Melperone) • Indoles (Sertindole, Ziprasidone) • Benzamides (Sulpiride, Remoxipride, Amisulpride) • diazepines/oxazepines/thiazepines (Clozapine, Olanzapine, Quetiapine) • other (Aripiprazole, Risperidone, Paliperidone, Asenapine, Iloperidone, Zotepine) |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
